ORPEA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.65 EUR | +2.58% |
|
+16.08% | -25.15% |
| Apr. 23 | ORPEA : Partial integration of the FY23 results |  |
| Apr. 19 | ORPEA : Ready for a refoundation full of thorns | |
| Sales 2023 | 5.2B 5.56B | Sales 2024 * | 5.44B 5.82B | Capitalization | 2.01B 2.16B |
|---|---|---|---|---|---|
| Net income 2023 * | -457M -489M | Net income 2024 * | -202M -216M | EV / Sales 2023 | 0.42 x |
| Net Debt 2023 * | 7.54B 8.07B | Net Debt 2024 * | 6.6B 7.07B | EV / Sales 2024 * | 1.58 x |
| P/E ratio 2023 * |
-
| P/E ratio 2024 * |
-0.01
x | Employees | 76,000 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on ORPEA
More press releases
More news
| 1 day | +2.58% | ||
| 1 week | +16.08% | ||
| Current month | +24.78% | ||
| 1 month | -4.46% | ||
| 3 months | -7.66% | ||
| 6 months | -98.96% | ||
| Current year | -25.15% |
1 week
10.70
13.25
1 month
9.9713.55
Current year
9.9718.10
1 year
9.973 046.00
3 years
9.97111 100.00
5 years
9.97129 000.00
10 years
9.97129 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Laurent Guillot
CEO | Chief Executive Officer | 54 | 22-06-30 |
Laurent Lemaire
DFI | Director of Finance/CFO | - | 21-12-07 |
| Chief Tech/Sci/R&D Officer | - | 22-10-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 65 | 22-07-27 | |
Laurent Guillot
CEO | Chief Executive Officer | 54 | 22-06-30 |
Mireille Faugère
BRD | Director/Board Member | 66 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.13% | 18 M€ | +2.56% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 12.65 | +2.58% | 458,869 |
| 24-04-22 | 12.33 | +0.67% | 133,967 |
| 24-04-19 | 12.25 | -1.95% | 334,692 |
| 24-04-18 | 12.49 | +11.83% | 637,469 |
| 24-04-17 | 11.17 | 0.00% | 171,228 |
Real-time Euronext Paris, April 23, 2024 at 11:35 am EDT
More quotes
ORPEA is the European leader in global dependency care. The group operates retirement homes, follow-up care clinics, and psychiatric clinics.
At the end of 2022, ORPEA had a network of 992 facilities (90,860 beds) located in France (358 facilities; 33,462 beds), Benelux/the United Kingdom/Ireland (193 facilities; 10,708 beds), Central Europe (237 facilities; 23,765 beds), Eastern Europe (124 facilities; 12,764 beds), the Iberian Peninsula and Latin America (79 facilities; 10,007 beds) and China (1 facility; 154 beds)
The group has a real estate portfolio of nearly 2.3 million m2 with a value of EUR 6,500 million.
Net sales are distributed geographically as follows: France/Benelux/the United Kingdom/Ireland (59.9%), Central Europe (25.6%), Eastern Europe (9.3%), Iberian Peninsula and Latin America (5.1%) and other (0.1%).
Calendar
2024-05-13
- Q1 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
12.65
EUR
Average target price
10,975
EUR
Spread / Average Target
+86,658.89%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.15% | 2.09B | |
| -21.76% | 1.49B | |
| -1.34% | 1.39B | |
| +19.07% | 1.25B | |
| +14.88% | 698M | |
| -4.55% | 457M | |
| +228.67% | 374M | |
| -8.05% | 324M | |
| -7.46% | 112M | |
| +30.51% | 84.47M |
- Stock Market
- Equities
- ORP Stock
